The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Absolutely Num4 and Stoney. We are due a milestone it is long overdue in my opinion as they are on the verge of Phase 2b or 3 on mono. All very exciting stuff esp. for long-term holders, as Thoth said lets see what the update says as it could well blow the doors off. I think wording along the lines of finding a breakthrough may just well do it, but a milestone payment would make an enormous difference to our share price and Sar's ability to move other programmes forward.
Indeed. I'm expecting more for PII since the upfront and transfer was small in comparison to other deals. Now they know it works as per pre-clinical data and they have a blockbuster, time to pay up.
I think Thoth has called it right....the details of milestones will have to be in the Sierra annual report listed as liabilities. I Num4 - if we are missing 12m it's just makes Thoths numbers higher :-)
Thoth, I think you've lost 12million somewhere, $88.4million was the amount due in milestones, we've had 2million. So $86.4million due.
Hi Thoth. Hope u are ok mate. How happy are you with progress of chk1 ? Is it better than u thought? Looks like lots of combo potential , hopefully lots of milestones. Thanks for u views
Num4- my guesstimate breakdown is P2 $8m P3 $16m NDA $25m marketing approval $25m and Sierra will need to raise loads of cash, as they will need to fund any parp combo trials as well, which is probably depressing their SP. Their annual report should be c 3rd March, which may give an indication of a provision for our next milestone.
Its on the sierra website. or you can listen to the webcast http://investor.sierraoncology.com/events-and-webcasts?item=23 The monotherapy is already in P2, and the combo about to move into P2. They seem to have amended the trial so that it is now a P1/2 rather than just P1. whether we have a subsequent P2b we dont know.
Have I missed something about us being in Phase 2 as I thought phase one was listed to be finished April 19? Appreciate the link in phase 2
Thoth, what breakdown would you give the deal for chk1? Are you expecting announcement from Sierra to include funding details going forward, they need another £100 million minimum to get the trials progressed and others started, thats also with the hope they can get commercial sales during the trials due to breakthrough announcement.
Aimsurfer. A couple of adjustments to your calcs. As we are now in p2. Entering p3 looks probable with c £12m milestone attached. 5 years is a reasonable average. But in diseases with no treatment optons available and poor prognosis (which criteria we meet in spades) its possible to be prescribed after p1. Lets see what clues we get on tuesday.
Well I’ve got my fingers crossed for ‘4p in 5 years’ (as was suggested in response to my last post here) on this high risk assessment. Honestly, I know is been a long run for a lot of holders here, but IMO I doubt it will be 4p in 5 years (MCAP ~110m). If CHK1 hits the wall we could be at .04p due to constant dilution to fund the other molecules or 14p+ given the revenue steam from CHK1 to fund the other molecules + licencing deals for TYK2 & Aurora. The CHK1 milestone payments are worth in the order of £48m.
We’ve broken 1p many a time in the last few years. Just haven’t held the rise. We need to smash 1p. Let’s see what the next few weeks brings. KR ZA
1.4p more realistic. 4p a dream come true 20p a dream.....
well after a mistimed buy on VAL I'd much rather SAR hit 20P first, I would be far more in profit ! I think the YA thing could drag on for a bit but news on 201/401 could drop anytime. But back to SAR, hopefully we will see some fireworks with SAR in the next week...
Yes - hey it suddenly got busy here as well.. Most eyes will be over there waiting for YA news. perfect time for the MM sneak attack here. Never tell me this is not done on purpose. Friday after the RNS, just like another minnow. I suppose the idea is you buy before any news, and any news may be Monday - just a question of which year. First one to 20p wins eh !
I certainly hope so. Are you still in VAL Herbie?
Nobody even cares it seems - but the big barrier has been breached - quiet before the storm ?